STAT+: How CVS is tapping into its consumer expertise in a new venture fund
CVS Health recently expanded its investing efforts with the launch of the CVS Venture Fund,…
Category: finance
.jpg)
There’s a gold rush in health tech. Here’s how the smart money stays ahead
Investors are pouring into the health tech sector, with venture funding roughly doubling in 2020….
STAT+: Ginkgo plans a $17.5 billion merger with SPAC that took DraftKings public
Ginkgo Bioworks, one of the hottest biotech startups in Massachusetts, said Tuesday that it plans…
STAT+: Global spending on medicines could hit $1.6 trillion by 2025 — and that doesn’t include Covid-19 vaccines
Global spending on medicines is forecast to grow between 3% and 6% annually and reach…
Opinion: STAT+: Investment in antimicrobials was up in 2020, but much work remains
The emergence of the Covid-19 pandemic generated renewed interest in the development of vaccines and…
STAT+: The field is exploding, but microbiome therapeutics still face a wave of challenges
Even as drug makers are poised to introduce actual medicines to change a person’s microbiome…
.jpg)
Opinion: To create value, pharma companies should prioritize innovation, not shareholders
Biogen announced its quarterly earnings on April 22 and revealed it had repurchased $600 million…
STAT+: Accolade to acquire PlushCare as telehealth competition intensifies
In a bid to beef up the services it can provide directly to customers, Accolade…
STAT+: Adagio raises $336 million to advance Covid-19 antibody treatment
Waltham-based Adagio Therapeutics announced on Monday that it has raised $336 million in new funding…
STAT+: Tango Therapeutics to go public in $353 million SPAC deal
Cambridge biotech Tango Therapeutics is going public through a $353 million deal with a special…
STAT+: Biotech venture capitalists have more money than ever to invest. What could possibly go wrong?
There’s more money sloshing around in biotech than ever before. Over the past year, several…
Medical device firms’ payments to doctors far outstripped those from pharma, study shows
WASHINGTON — The medical device industry gave doctors consulting fees, lunches, lodging, and other incentive…
STAT+: Lilly is a holdout among companies that agree to disclose when executive pay is clawed back
A coalition of institutional investors is pushing Eli Lilly to adopt a policy to disclose…
STAT+: The health tech tracker for the second quarter: 15 pivotal industry events to watch
Securing a billion dollars of yearly funding was once considered a landmark achievement in health…
STAT+: Behind the scenes, companies helping big Covid-19 vaccine makers are getting rich
Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from…
STAT+: Microbiome company Finch Therapeutics begins trading publicly, quietly shuffles one of its executives
Microbiome company Finch Therapeutics is, officially, worth about $960 million. Shares in the company began…
STAT+: How the wave of telehealth SPACs during the pandemic could create a ‘perfect storm’ for investors
In little more than a year, telehealth has gone from a backwater of American health…
STAT+: AmerisourceBergen say-on-pay proposal squeaks by amid outrage over CEO compensation
In a rebuke to AmerisourceBergen (ABC), nearly half of its shareholders voted against a “say-on-pay”…
STAT+: VC firm General Catalyst taps expertise of former Ancestry, Livongo, and Gilead executives
General Catalyst’s Hemant Taneja realized he had created a unique playbook for health care startups…
‘Deeply problematic’: AmerisourceBergen rewards its CEO despite the ravages of the opioid crisis
You can file this under, “What opioid crisis?” In one of the more startling examples…
STAT+: Cigna’s Evernorth to acquire telehealth company MDLive
Riding a wave of pandemic-fueled momentum for virtual care, Cigna subsidiary Evernorth is acquiring telehealth…
STAT+: Once again, the credit outlook for the pharmaceutical industry is negative
For the eighth consecutive year, the credit outlook for the pharmaceutical industry is negative and…
Pharma’s ambitious new antibiotic venture hires a CEO to fix a ‘broken’ pipeline
Several months after a splashy announcement, an ambitious pharmaceutical industry venture to tackle antibiotic resistance…
STAT+: At Flagship Pioneering, the brazen venture capital firm that bankrolled Moderna, there’s a tolerance for failure but not for weakness
Not long ago, the name Flagship Pioneering was as likely to elicit an eye roll…
STAT+: Zocdoc, staking its future on the promise of hybrid care, raises $150 million
Less than a year since Zocdoc reinvented itself as a telehealth platform in the face…
Listen: 23andMe is going public, vaccine data abound, and Merck’s CEO is retiring
Is consumer DNA testing a good business? Are Covid-19 vaccines interchangeable? And how do you…
23andMe to go public via Richard Branson’s SPAC
The genetics testing company 23andMe will enter the public markets via a special purpose acquisition…
STAT+: Will the FTC get tougher on pharma business practices under the Biden administration?
As the Biden administration begins setting priorities, the Federal Trade Commission is poised to take…
STAT+: What comes after the telehealth boom? Hybrid care models are drawing investor interest
Buoyed by the pandemic, 2020 was undoubtedly the year that telehealth turned the corner to…
STAT+: After repeated FDA rejections, key investor writes down stake in former diabetes unicorn Intarcia Therapeutics
Intarcia Therapeutics, a one-time biotech unicorn that has been unable to secure approval for a…
Major health companies and trade groups suspend campaign contributions after Capitol riot
WASHINGTON — Following last week’s riot here, several major health care corporations are re-evaluating their…
STAT+: Triplet Therapeutics and three other startups got venture funding a year ago. Where are they now?
In a typical year, a biotech startup might hope to raise enough money to keep…
Haven, ambitious health venture backed by Amazon, to shut down
After a tumultuous three years marked by halting progress and high rates of employee turnover,…
Opinion: Incentives and information drive health care innovation: lessons from Medicare Advantage
Health care in America often feels like it moves at a glacial pace, if that…
Opinion: We stress tested banks in 2009. We need to do the same thing now for U.S. hospital systems
Following the market turmoil after the failure of Lehman Brothers in the fall of 2008,…
STAT+: How 2020 became the year of the biotech SPAC
Over the past year, the humble blank-check IPO has risen from a disreputable relic of…
STAT+: The most impressive biotech VCs of 2020
Behind almost every biotech IPO, every merger, and every buyout are a set of venture…
STAT+: AstraZeneca to acquire Alexion for $39 billion, adding blockbuster immune medicines
AstraZeneca on Saturday said it was acquiring Alexion Pharmaceuticals for $39 billion, marking a significant…
Opinion: STAT+: In biopharma mergers and acquisitions, managing regulatory compliance early protects return on investment
Mergers and acquisitions have long been a vehicle for growth in the pharmaceutical industry. They…
STAT+: Months of limbo at OpenBiome put fecal matter transplants on hold across the country
New regulations put in place because of Covid-19 have left one of the largest U.S….
STAT Plus: Not by the numbers: Former Aceto controller is charged with insider trading
File this under ‘What was he thinking?’ After spending nearly 17 years as controller at…
STAT Plus: Novartis sells bonds tied to expanding access to medicines in poor countries
In a first-of-its-kind move by a large drug maker, Novartis (NVS) raised approximately $2.1 billion…
Opinion: When private equity firms invest in women’s health clinics, who benefits?
As the Covid-19 pandemic continues to surge in the United States, Americans are becoming more…
STAT Plus: How much is a startup worth? For biotech companies, the answer is rarely public
Valuations are fundamental information about any startup. Not only can high valuations give a company…
STAT Plus: Is the Covid-19 pandemic a tipping point for digital health?
Covid-19 may turn out to be digital health’s tipping point, two Silicon Valley venture capitalists…
STAT Plus: Oncorus and three other startups got venture funding a year ago. Did it help them do what they said it would?
Most biotech startups are free to tell the world as little or as much as…
STAT Plus: Biofourmis raises $100 million for remote patient monitoring tools
Biofourmis, a Boston startup that makes technology to remotely monitor patients with chronic conditions and…
STAT Plus: What we learned about the business of telemedicine from Amwell and GoodRx’s IPO filings
Last week, two virtual care providers filed paperwork to go public — offering an unprecedented…
STAT Plus: Otsuka approved to buy bankrupt smart-pill maker Proteus’ assets, overcoming effort by Novartis to block purchase
The Japanese drug maker Otsuka has been approved to purchase the assets of bankrupt smart…
STAT Plus: How Teladoc won: The inside story of how well-timed bets propelled it ahead of the competition
The unquestioned leader in a virtual care sector that has surged in the Covid-19 era,…